Lanean...
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma
The oral multikinase inhibitor sunitinib malate was approved by the U.S. Food and Drug Administration in January 2006 for use in patients with advanced renal cell carcinoma (RCC). Since then, it has been approved globally for this indication and for patients with imatinib‐resistant or ‐intolerant ga...
Gorde:
| Argitaratua izan da: | Oncologist |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Wiley-Blackwell
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5313263/ https://ncbi.nlm.nih.gov/pubmed/27807302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0197 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|